Accordingly, we silenced AR expression in a panel of melanoma cells harboring either BRAF or NRAS mutations individually and in combination with TP53, PTEN, and/or CDK4 mutations (Fig. S3, A and B). This evidence concerns the gene NRAS and melanoma.